{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T00:15:15Z","timestamp":1793837715567,"version":"4.6.1"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,7,19]],"date-time":"2019-07-19T00:00:00Z","timestamp":1563494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,7,19]],"date-time":"2019-07-19T00:00:00Z","timestamp":1563494400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Virus-neutralizing antibodies are a severe obstacle in oncolytic virotherapy. Here, we present a strategy to convert this unfavorable immune response into an anticancer immunotherapy via molecular retargeting. Application of a bifunctional adapter harboring a tumor-specific ligand and the adenovirus hexon domain DE1 for engaging antiadenoviral antibodies, attenuates tumor growth and prolongs survival in adenovirus-immunized mice. The therapeutic benefit achieved by tumor retargeting of antiviral antibodies is largely due to NK cell-mediated triggering of tumor-directed CD8 T-cells. We further demonstrate that antibody-retargeting (Ab-retargeting) is a feasible method to sensitize tumors to PD-1 immune checkpoint blockade. In therapeutic settings, Ab-retargeting greatly improves the outcome of intratumor application of an oncolytic adenovirus and facilitates long-term survival in treated animals when combined with PD-1 checkpoint inhibition. Tumor-directed retargeting of preexisting or virotherapy-induced antiviral antibodies therefore represents a promising strategy to fully exploit the immunotherapeutic potential of oncolytic virotherapy and checkpoint inhibition.<\/jats:p>","DOI":"10.1038\/s41467-019-11137-5","type":"journal-article","created":{"date-parts":[[2019,7,19]],"date-time":"2019-07-19T10:03:00Z","timestamp":1563530580000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":63,"title":["Molecular retargeting of antibodies converts immune defense against oncolytic viruses into cancer immunotherapy"],"prefix":"10.1038","volume":"10","author":[{"given":"Julia","family":"Niemann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norman","family":"Woller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Brooks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bettina","family":"Fleischmann-Mundt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolas T.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnold","family":"Kloos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Knocke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda M.","family":"Ernst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"Manns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Kubicka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas C.","family":"Wirth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5796-368X","authenticated-orcid":false,"given":"Rita","family":"Gerardy-Schahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6942-1573","authenticated-orcid":false,"given":"Florian","family":"K\u00fchnel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,7,19]]},"reference":[{"key":"11137_CR1","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1038\/nbt.2287","volume":"30","author":"SJ Russell","year":"2012","unstructured":"Russell, S. J., Peng, K. W. & Bell, J. C. Oncolytic virotherapy. Nat. Biotechnol. 30, 658\u2013670 (2012).","journal-title":"Nat. Biotechnol."},{"key":"11137_CR2","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.4161\/cbt.7.8.6216","volume":"7","author":"F Benencia","year":"2008","unstructured":"Benencia, F., Courreges, M. C., Fraser, N. W. & Coukos, G. Herpes virus oncolytic therapy reverses tumor immune dysfunction and facilitates tumor antigen presentation. Cancer Biol. Ther. 7, 1194\u20131205 (2008).","journal-title":"Cancer Biol. Ther."},{"key":"11137_CR3","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1038\/gt.2008.58","volume":"15","author":"F Errington","year":"2008","unstructured":"Errington, F. et al. Inflammatory tumour cell killing by oncolytic reovirus for the treatment of melanoma. Gene Ther. 15, 1257\u20131270 (2008).","journal-title":"Gene Ther."},{"key":"11137_CR4","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1038\/sj.mt.6300215","volume":"15","author":"CJ Breitbach","year":"2007","unstructured":"Breitbach, C. J. et al. Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow. Mol. Ther. 15, 1686\u20131693 (2007).","journal-title":"Mol. Ther."},{"key":"11137_CR5","doi-asserted-by":"publisher","first-page":"5763","DOI":"10.1200\/JCO.2009.24.3675","volume":"27","author":"NN Senzer","year":"2009","unstructured":"Senzer, N. N. et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J. Clin. Oncol. 27, 5763\u20135771 (2009).","journal-title":"J. Clin. Oncol."},{"key":"11137_CR6","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","volume":"33","author":"RH Andtbacka","year":"2015","unstructured":"Andtbacka, R. H. et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J. Clin. Oncol. 33, 2780\u20132788 (2015).","journal-title":"J. Clin. Oncol."},{"key":"11137_CR7","doi-asserted-by":"publisher","first-page":"12873","DOI":"10.1073\/pnas.0605496103","volume":"103","author":"G Fulci","year":"2006","unstructured":"Fulci, G. et al. Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. Proc. Natl Acad. Sci. USA 103, 12873\u201312878 (2006).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"11137_CR8","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1038\/mt.2008.162","volume":"16","author":"MA Thomas","year":"2008","unstructured":"Thomas, M. A. et al. Immunosuppression enhances oncolytic adenovirus replication and antitumor efficacy in the Syrian hamster model. Mol. Ther. 16, 1665\u20131673 (2008).","journal-title":"Mol. Ther."},{"key":"11137_CR9","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1089\/10430340050083289","volume":"11","author":"Y Chen","year":"2000","unstructured":"Chen, Y., Yu, D. C., Charlton, D. & Henderson, D. R. Pre-existent adenovirus antibody inhibits systemic toxicity and antitumor activity of CN706 in the nude mouse LNCaP xenograft model: implications and proposals for human therapy. Hum. Gene Ther. 11, 1553\u20131567 (2000).","journal-title":"Hum. Gene Ther."},{"key":"11137_CR10","doi-asserted-by":"publisher","first-page":"78","DOI":"10.3390\/v2010078","volume":"2","author":"HH Wong","year":"2010","unstructured":"Wong, H. H., Lemoine, N. R. & Wang, Y. Oncolytic viruses for cancer therapy: overcoming the obstacles. Viruses 2, 78\u2013106 (2010).","journal-title":"Viruses"},{"key":"11137_CR11","doi-asserted-by":"publisher","first-page":"19976","DOI":"10.18632\/oncotarget.5116","volume":"6","author":"C Larson","year":"2015","unstructured":"Larson, C. et al. Going viral: a review of replication-selective oncolytic adenoviruses. Oncotarget 6, 19976\u201319989 (2015).","journal-title":"Oncotarget"},{"key":"11137_CR12","doi-asserted-by":"publisher","first-page":"7802","DOI":"10.1038\/sj.onc.1209037","volume":"24","author":"M Aghi","year":"2005","unstructured":"Aghi, M. & Martuza, R. L. Oncolytic viral therapies - the clinical experience. Oncogene 24, 7802\u20137816 (2005).","journal-title":"Oncogene"},{"key":"11137_CR13","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1200\/JCO.2017.75.8219","volume":"36","author":"FF Lang","year":"2018","unstructured":"Lang, F. F. et al. Phase I study of DNX-2401 (Delta-24-RGD) oncolytic adenovirus: replication and immunotherapeutic effects in recurrent malignant glioma. J. Clin. Oncol. 36, 1419\u20131427 (2018).","journal-title":"J. Clin. Oncol."},{"key":"11137_CR14","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1128\/JVI.06254-11","volume":"86","author":"RR Bradley","year":"2012","unstructured":"Bradley, R. R., Lynch, D. M., Iampietro, M. J., Borducchi, E. N. & Barouch, D. H. Adenovirus serotype 5 neutralizing antibodies target both hexon and fiber following vaccination and natural infection. J. Virol. 86, 625\u2013629 (2012).","journal-title":"J. Virol."},{"key":"11137_CR15","doi-asserted-by":"publisher","first-page":"7179","DOI":"10.4049\/jimmunol.174.11.7179","volume":"174","author":"SM Sumida","year":"2005","unstructured":"Sumida, S. M. et al. Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein. J. Immunol. 174, 7179\u20137185 (2005).","journal-title":"J. Immunol."},{"key":"11137_CR16","doi-asserted-by":"publisher","first-page":"10366","DOI":"10.1128\/JVI.77.19.10366-10375.2003","volume":"77","author":"SS Hong","year":"2003","unstructured":"Hong, S. S., Habib, N. A., Franqueville, L., Jensen, S. & Boulanger, P. A. Identification of adenovirus (ad) penton base neutralizing epitopes by use of sera from patients who had received conditionally replicative ad (addl1520) for treatment of liver tumors. J. Virol. 77, 10366\u201310375 (2003).","journal-title":"J. Virol."},{"key":"11137_CR17","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1128\/JVI.02127-08","volume":"83","author":"D Dhar","year":"2009","unstructured":"Dhar, D., Spencer, J. F., Toth, K. & Wold, W. S. Effect of preexisting immunity on oncolytic adenovirus vector INGN 007 antitumor efficacy in immunocompetent and immunosuppressed Syrian hamsters. J. Virol. 83, 2130\u20132139 (2009).","journal-title":"J. Virol."},{"key":"11137_CR18","doi-asserted-by":"publisher","first-page":"8263","DOI":"10.1128\/JVI.77.15.8263-8271.2003","volume":"77","author":"R Vogels","year":"2003","unstructured":"Vogels, R. et al. Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. J. Virol. 77, 8263\u20138271 (2003).","journal-title":"J. Virol."},{"key":"11137_CR19","doi-asserted-by":"crossref","first-page":"6875","DOI":"10.1128\/JVI.72.8.6875-6879.1998","volume":"72","author":"S Roy","year":"1998","unstructured":"Roy, S., Shirley, P. S., McClelland, A. & Kaleko, M. Circumvention of immunity to the adenovirus major coat protein hexon. J. Virol. 72, 6875\u20136879 (1998).","journal-title":"J. Virol."},{"key":"11137_CR20","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/sj.gt.3301389","volume":"8","author":"KD Fisher","year":"2001","unstructured":"Fisher, K. D. et al. Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies. Gene Ther. 8, 341\u2013348 (2001).","journal-title":"Gene Ther."},{"key":"11137_CR21","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1089\/hum.2007.034","volume":"18","author":"T Hakkarainen","year":"2007","unstructured":"Hakkarainen, T. et al. Human mesenchymal stem cells lack tumor tropism but enhance the antitumor activity of oncolytic adenoviruses in orthotopic lung and breast tumors. Hum. Gene Ther. 18, 627\u2013641 (2007).","journal-title":"Hum. Gene Ther."},{"key":"11137_CR22","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1158\/1078-0432.CCR-06-1726","volume":"13","author":"J Kurai","year":"2007","unstructured":"Kurai, J. et al. Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines. Clin. Cancer Res. 13, 1552\u20131561 (2007).","journal-title":"Clin. Cancer Res."},{"key":"11137_CR23","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/74704","volume":"6","author":"RA Clynes","year":"2000","unstructured":"Clynes, R. A., Towers, T. L., Presta, L. G. & Ravetch, J. V. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat. Med. 6, 443\u2013446 (2000).","journal-title":"Nat. Med."},{"key":"11137_CR24","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1016\/S0301-472X(99)00089-2","volume":"27","author":"S Cooley","year":"1999","unstructured":"Cooley, S., Burns, L. J., Repka, T. & Miller, J. S. Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2\/neu. Exp. Hematol. 27, 1533\u20131541 (1999).","journal-title":"Exp. Hematol."},{"key":"11137_CR25","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1006\/mthe.1999.0001","volume":"1","author":"JJ Rux","year":"2000","unstructured":"Rux, J. J. & Burnett, R. M. Type-specific epitope locations revealed by X-ray crystallographic study of adenovirus type 5 hexon. Mol. Ther. 1, 18\u201330 (2000).","journal-title":"Mol. Ther."},{"key":"11137_CR26","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1128\/JVI.02023-06","volume":"81","author":"SL Pichla-Gollon","year":"2007","unstructured":"Pichla-Gollon, S. L. et al. Structure-based identification of a major neutralizing site in an adenovirus hexon. J. Virol. 81, 1680\u20131689 (2007).","journal-title":"J. Virol."},{"key":"11137_CR27","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1128\/JVI.06165-11","volume":"86","author":"RR Bradley","year":"2012","unstructured":"Bradley, R. R. et al. Adenovirus serotype 5-specific neutralizing antibodies target multiple hexon hypervariable regions. J. Virol. 86, 1267\u20131272 (2012).","journal-title":"J. Virol."},{"key":"11137_CR28","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/nature04721","volume":"441","author":"DM Roberts","year":"2006","unstructured":"Roberts, D. M. et al. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature 441, 239\u2013243 (2006).","journal-title":"Nature"},{"key":"11137_CR29","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1158\/2326-6066.CIR-14-0124-T","volume":"3","author":"A Kloos","year":"2015","unstructured":"Kloos, A. et al. PolySia-specific retargeting of oncolytic viruses triggers tumor-specific immune responses and facilitates therapy of disseminated lung cancer. Cancer Immunol. Res. 3, 751\u2013763 (2015).","journal-title":"Cancer Immunol. Res."},{"key":"11137_CR30","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/bjc.1998.450","volume":"78","author":"S Gluer","year":"1998","unstructured":"Gluer, S. et al. Serum polysialylated neural cell adhesion molecule in childhood neuroblastoma. Br. J. Cancer 78, 106\u2013110 (1998).","journal-title":"Br. J. Cancer"},{"key":"11137_CR31","doi-asserted-by":"publisher","first-page":"925","DOI":"10.2174\/156800912803251225","volume":"12","author":"RA Falconer","year":"2012","unstructured":"Falconer, R. A., Errington, R. J., Shnyder, S. D., Smith, P. J. & Patterson, L. H. Polysialyltransferase: a new target in metastatic cancer. Curr. Cancer Drug Targets 12, 925\u2013939 (2012).","journal-title":"Curr. Cancer Drug Targets"},{"key":"11137_CR32","doi-asserted-by":"publisher","first-page":"5229","DOI":"10.1158\/1078-0432.CCR-15-2971","volume":"22","author":"S Trivedi","year":"2016","unstructured":"Trivedi, S. et al. Anti-EGFR targeted monoclonal antibody isotype influences antitumor cellular immunity in head and neck cancer patients. Clin. Cancer Res. 22, 5229\u20135237 (2016).","journal-title":"Clin. Cancer Res."},{"key":"11137_CR33","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/nature14001","volume":"515","author":"M Yadav","year":"2014","unstructured":"Yadav, M. et al. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature 515, 572\u2013576 (2014).","journal-title":"Nature"},{"key":"11137_CR34","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1158\/0008-5472.CAN-11-3722","volume":"72","author":"JC Castle","year":"2012","unstructured":"Castle, J. C. et al. Exploiting the mutanome for tumor vaccination. Cancer Res. 72, 1081\u20131091 (2012).","journal-title":"Cancer Res."},{"key":"11137_CR35","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1038\/mt.2015.115","volume":"23","author":"N Woller","year":"2015","unstructured":"Woller, N. et al. Viral infection of tumors overcomes resistance to PD-1-immunotherapy by broadening neoantigenome-directed T-cell responses. Mol. Ther. 23, 1630\u20131640 (2015).","journal-title":"Mol. Ther."},{"key":"11137_CR36","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1073\/pnas.88.2.350","volume":"88","author":"JJ O\u2019Shea","year":"1991","unstructured":"O\u2019Shea, J. J., Weissman, A. M., Kennedy, I. C. & Ortaldo, J. R. Engagement of the natural killer cell IgG Fc receptor results in tyrosine phosphorylation of the zeta chain. Proc. Natl Acad. Sci. USA 88, 350\u2013354 (1991).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"11137_CR37","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.immuni.2017.06.019","volume":"47","author":"HS Dai","year":"2017","unstructured":"Dai, H. S. et al. The Fc domain of immunoglobulin is sufficient to bridge NK cells with virally infected cells. Immunity 47, 159\u2013170 (2017).","journal-title":"Immunity"},{"key":"11137_CR38","doi-asserted-by":"publisher","first-page":"5134","DOI":"10.1158\/0008-5472.CAN-10-4222","volume":"71","author":"P Hubert","year":"2011","unstructured":"Hubert, P. et al. Antibody-dependent cell cytotoxicity synapses form in mice during tumor-specific antibody immunotherapy. Cancer Res. 71, 5134\u20135143 (2011).","journal-title":"Cancer Res."},{"key":"11137_CR39","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jim.2004.08.008","volume":"294","author":"G Alter","year":"2004","unstructured":"Alter, G., Malenfant, J. M. & Altfeld, M. CD107a as a functional marker for the identification of natural killer cell activity. J. Immunol. Methods 294, 15\u201322 (2004).","journal-title":"J. Immunol. Methods"},{"key":"11137_CR40","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/eji.200939903","volume":"40","author":"L Dolcetti","year":"2010","unstructured":"Dolcetti, L. et al. Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF. Eur. J. Immunol. 40, 22\u201335 (2010).","journal-title":"Eur. J. Immunol."},{"key":"11137_CR41","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/j.immuni.2014.10.020","volume":"41","author":"JM Haverkamp","year":"2014","unstructured":"Haverkamp, J. M. et al. Myeloid-derived suppressor activity is mediated by monocytic lineages maintained by continuous inhibition of extrinsic and intrinsic death pathways. Immunity 41, 947\u2013959 (2014).","journal-title":"Immunity"},{"key":"11137_CR42","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1172\/JCI41264","volume":"120","author":"SN Waggoner","year":"2010","unstructured":"Waggoner, S. N., Taniguchi, R. T., Mathew, P. A., Kumar, V. & Welsh, R. M. Absence of mouse 2B4 promotes NK cell-mediated killing of activated CD8\u2009+\u2009T cells, leading to prolonged viral persistence and altered pathogenesis. J. Clin. Invest. 120, 1925\u20131938 (2010).","journal-title":"J. Clin. Invest."},{"key":"11137_CR43","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.4049\/jimmunol.1103474","volume":"189","author":"MQ Ge","year":"2012","unstructured":"Ge, M. Q. et al. NK cells regulate CD8\u2009+\u2009T cell priming and dendritic cell migration during influenza A infection by IFN-gamma and perforin-dependent mechanisms. J. Immunol. 189, 2099\u20132109 (2012).","journal-title":"J. Immunol."},{"key":"11137_CR44","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1158\/1078-0432.CCR-12-2426","volume":"19","author":"RM Srivastava","year":"2013","unstructured":"Srivastava, R. M. et al. Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients. Clin. Cancer Res. 19, 1858\u20131872 (2013).","journal-title":"Clin. Cancer Res."},{"key":"11137_CR45","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1182\/blood-2004-09-3775","volume":"106","author":"C Adam","year":"2005","unstructured":"Adam, C. et al. DC-NK cell cross talk as a novel CD4\u2009+\u2009T-cell-independent pathway for antitumor CTL induction. Blood 106, 338\u2013344 (2005).","journal-title":"Blood"},{"key":"11137_CR46","first-page":"3181","volume":"63","author":"T Wirth","year":"2003","unstructured":"Wirth, T. et al. A telomerase-dependent conditionally replicating adenovirus for selective treatment of cancer. Cancer Res. 63, 3181\u20133188 (2003).","journal-title":"Cancer Res."},{"key":"11137_CR47","doi-asserted-by":"publisher","first-page":"7478","DOI":"10.1128\/JVI.79.12.7478-7491.2005","volume":"79","author":"DM Shayakhmetov","year":"2005","unstructured":"Shayakhmetov, D. M., Gaggar, A., Ni, S., Li, Z. Y. & Lieber, A. Adenovirus binding to blood factors results in liver cell infection and hepatotoxicity. J. Virol. 79, 7478\u20137491 (2005).","journal-title":"J. Virol."},{"key":"11137_CR48","doi-asserted-by":"publisher","first-page":"11705","DOI":"10.1128\/JVI.01320-08","volume":"82","author":"Z Xu","year":"2008","unstructured":"Xu, Z., Tian, J., Smith, J. S. & Byrnes, A. P. Clearance of adenovirus by Kupffer cells is mediated by scavenger receptors, natural antibodies, and complement. J. Virol. 82, 11705\u201311713 (2008).","journal-title":"J. Virol."},{"key":"11137_CR49","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1056\/NEJMoa1302369","volume":"369","author":"JD Wolchok","year":"2013","unstructured":"Wolchok, J. D. et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369, 122\u2013133 (2013).","journal-title":"N. Engl. J. Med."},{"key":"11137_CR50","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","volume":"371","author":"A Snyder","year":"2014","unstructured":"Snyder, A. et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 371, 2189\u20132199 (2014).","journal-title":"N. Engl. J. Med."},{"key":"11137_CR51","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1089\/hum.2013.235","volume":"25","author":"D Majhen","year":"2014","unstructured":"Majhen, D. et al. Adenovirus-based vaccines for fighting infectious diseases and cancer: progress in the field. Hum. Gene Ther. 25, 301\u2013317 (2014).","journal-title":"Hum. Gene Ther."},{"key":"11137_CR52","doi-asserted-by":"publisher","first-page":"307","DOI":"10.2174\/156652311796150372","volume":"11","author":"YS Ahi","year":"2011","unstructured":"Ahi, Y. S., Bangari, D. S. & Mittal, S. K. Adenoviral vector immunity: its implications and circumvention strategies. Curr. Gene Ther. 11, 307\u2013320 (2011).","journal-title":"Curr. Gene Ther."},{"key":"11137_CR53","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/j.ymthe.2018.01.019","volume":"26","author":"JM Ricca","year":"2018","unstructured":"Ricca, J. M. et al. Pre-existing immunity to oncolytic virus potentiates its immunotherapeutic efficacy. Mol. Ther. 26, 1008\u20131019 (2018).","journal-title":"Mol. Ther."},{"key":"11137_CR54","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1002\/jgm.1332","volume":"11","author":"S Abe","year":"2009","unstructured":"Abe, S. et al. Adenovirus type 5 with modified hexons induces robust transgene-specific immune responses in mice with pre-existing immunity against adenovirus type 5. J. Gene Med. 11, 570\u2013579 (2009).","journal-title":"J. Gene Med."},{"key":"11137_CR55","doi-asserted-by":"publisher","first-page":"185ra63","DOI":"10.1126\/scitranslmed.3005361","volume":"5","author":"MK Kim","year":"2013","unstructured":"Kim, M. K. et al. Oncolytic and immunotherapeutic vaccinia induces antibody-mediated complement-dependent cancer cell lysis in humans. Sci. Transl. Med. 5, 185ra63 (2013).","journal-title":"Sci. Transl. Med."},{"key":"11137_CR56","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/S1074-7613(03)00264-4","volume":"19","author":"R Mocikat","year":"2003","unstructured":"Mocikat, R. et al. Natural killer cells activated by MHC class I(low) targets prime dendritic cells to induce protective CD8 T cell responses. Immunity 19, 561\u2013569 (2003).","journal-title":"Immunity"},{"key":"11137_CR57","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1038\/ni.1937","volume":"11","author":"SK Biswas","year":"2010","unstructured":"Biswas, S. K. & Mantovani, A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat. Immunol. 11, 889\u2013896 (2010).","journal-title":"Nat. Immunol."},{"key":"11137_CR58","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1136\/gutjnl-2015-309193","volume":"65","author":"G Di Caro","year":"2015","unstructured":"Di Caro, G. et al. Dual prognostic significance of tumour-associated macrophages in human pancreatic adenocarcinoma treated or untreated with chemotherapy. Gut 65, 1710\u20131720 (2015).","journal-title":"Gut"},{"key":"11137_CR59","doi-asserted-by":"publisher","first-page":"4583","DOI":"10.4049\/jimmunol.175.7.4583","volume":"175","author":"S Kusmartsev","year":"2005","unstructured":"Kusmartsev, S., Nagaraj, S. & Gabrilovich, D. I. Tumor-associated CD8\u2009+\u2009T cell tolerance induced by bone marrow-derived immature myeloid cells. J. Immunol. 175, 4583\u20134592 (2005).","journal-title":"J. Immunol."},{"key":"11137_CR60","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1053\/j.gastro.2015.04.010","volume":"149","author":"GL Beatty","year":"2015","unstructured":"Beatty, G. L. et al. Exclusion of T cells from pancreatic carcinomas in mice is regulated by Ly6C(low) F4\/80(\u2009+\u2009) extratumoral macrophages. Gastroenterology 149, 201\u2013210 (2015).","journal-title":"Gastroenterology"},{"key":"11137_CR61","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1158\/2159-8290.CD-15-0944","volume":"6","author":"SJ Blake","year":"2016","unstructured":"Blake, S. J. et al. Suppression of metastases using a new lymphocyte checkpoint target for cancer immunotherapy. Cancer Discov. 6, 446\u2013459 (2016).","journal-title":"Cancer Discov."},{"key":"11137_CR62","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1172\/JCI97611","volume":"128","author":"PJ Chockley","year":"2018","unstructured":"Chockley, P. J. et al. Epithelial-mesenchymal transition leads to NK cell-mediated metastasis-specific immunosurveillance in lung cancer. J. Clin. Invest. 128, 1384\u20131396 (2018).","journal-title":"J. Clin. Invest."},{"key":"11137_CR63","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1038\/mt.2014.160","volume":"22","author":"CE Engeland","year":"2014","unstructured":"Engeland, C. E. et al. CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy. Mol. Ther. 22, 1949\u20131959 (2014).","journal-title":"Mol. Ther."},{"key":"11137_CR64","doi-asserted-by":"publisher","first-page":"226ra32","DOI":"10.1126\/scitranslmed.3008095","volume":"6","author":"D Zamarin","year":"2014","unstructured":"Zamarin, D. et al. Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci. Transl. Med. 6, 226ra32 (2014).","journal-title":"Sci. Transl. Med."},{"key":"11137_CR65","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.cell.2017.08.027","volume":"170","author":"A Ribas","year":"2017","unstructured":"Ribas, A. et al. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell 170, 1109\u20131119 (2017).","journal-title":"Cell"},{"key":"11137_CR66","doi-asserted-by":"publisher","first-page":"4981","DOI":"10.4049\/jimmunol.1202017","volume":"189","author":"LP Ganesan","year":"2012","unstructured":"Ganesan, L. P. et al. FcgammaRIIb on liver sinusoidal endothelium clears small immune complexes. J. Immunol. 189, 4981\u20134988 (2012).","journal-title":"J. Immunol."},{"issue":"Pt 18","key":"11137_CR67","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.1242\/jcs.113.18.3255","volume":"113","author":"T Lovdal","year":"2000","unstructured":"Lovdal, T., Andersen, E., Brech, A. & Berg, T. Fc receptor mediated endocytosis of small soluble immunoglobulin G immune complexes in Kupffer and endothelial cells from rat liver. J. Cell Sci. 113(Pt 18), 3255\u20133266 (2000).","journal-title":"J. Cell Sci."},{"key":"11137_CR68","doi-asserted-by":"publisher","first-page":"W597","DOI":"10.1093\/nar\/gks400","volume":"40","author":"P Artimo","year":"2012","unstructured":"Artimo, P. et al. ExPASy: SIB bioinformatics resource portal. Nucleic Acids Res. 40, W597\u2013W603 (2012).","journal-title":"Nucleic Acids Res."},{"key":"11137_CR69","doi-asserted-by":"publisher","first-page":"W296","DOI":"10.1093\/nar\/gky427","volume":"46","author":"A Waterhouse","year":"2018","unstructured":"Waterhouse, A. et al. SWISS-MODEL: homology modelling of protein structures and complexes. Nucleic Acids Res. 46, W296\u2013W303 (2018).","journal-title":"Nucleic Acids Res."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-11137-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-11137-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-11137-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T00:25:16Z","timestamp":1671236716000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-11137-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,19]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["11137"],"URL":"https:\/\/doi.org\/10.1038\/s41467-019-11137-5","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,19]]},"assertion":[{"value":"7 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3236"}}